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Tumor necrosis factor alpha (TNF-) is a critical mediator of inflammation, and its production is tightly
regulated, with control points operating at nearly every step of its biosynthesis. We sought to identify unchar-
acterized TNF- 3 untranslated region (3UTR)-interacting proteins utilizing a novel screen, termed the RNA
capture assay. We identified CARHSP1, a cold-shock domain-containing protein. Knockdown of CARHSP1
inhibits TNF- protein production in lipopolysaccharide (LPS)-stimulated cells and reduces the level of
TNF- mRNA in both resting and LPS-stimulated cells. mRNA stability assays demonstrate that CARHSP1
knockdown decreases TNF- mRNA stability from a half-life (t1/2) of 49 min to a t1/2 of 22 min in LPS-
stimulated cells and from a t1/2 of 29 min to a t1/2 of 24 min in resting cells. Transfecting CARHSP1 into
RAW264.7 cells results in an increase in TNF- 3UTR luciferase expression in resting cells and CARHSP1
knockdown LPS-stimulated cells. We examined the functional effect of inhibiting Akt, calcineurin, and protein
phosphatase 2A and established that inhibition of Akt or calcineurin but not PP2A inhibits CARHSP1
function. Subcellular analysis establishes CARHSP1 as a cytoplasmic protein localizing to processing bodies
and exosomes but not on translating mRNAs. We conclude CARHSP1 is a TNF- mRNA stability enhancer
required for effective TNF- production, demonstrating the importance of both stabilization and destabiliza-
tion pathways in regulating the TNF- mRNA half-life.
Tumor necrosis factor alpha (TNF-) is a pleiotropic cyto-
kine and a central mediator of inflammation. TNF- plays a
critical role in the host response to infection and injury, and
the rapid, local production of TNF- is critical to the imme-
diate control of infection and the subsequent immune re-
sponse. Overexpression of TNF- can lead to severe tissue
damage and underlies a number of disease states, including
rheumatoid arthritis, Crohn’s disease, and cachexia, as well as
contributing to the pathologies associated with traumatic brain
injury (4, 15, 18).
TNF- biosynthesis is controlled by transcriptional and post-
transcriptional mechanisms, with regulatory control points at
virtually every step of its synthesis; this complex control allows
for rapid, transient production (1). Posttranscriptional regula-
tion of TNF- operates through cis elements in the 3 untrans-
lated region (3UTR) of the mRNA, which serve as binding
sites for trans-acting proteins. One of the best-studied cis ele-
ments is the AU-rich element (ARE), which is critical in the
regulation of TNF- message nuclear export, stability, and
translation (3, 4, 12, 15, 16, 24, 28). In resting cells, the TNF-
message is unstable and translationally repressed, severely lim-
iting TNF- protein production (3, 12, 16, 28). In response to
lipopolysaccharide (LPS) stimulation, monocytes/macrophages
stabilize the TNF- message and translation is derepressed,
allowing for the rapid production of TNF- protein (3, 12, 16,
24, 28). The importance of ARE-mediated TNF- posttran-
scriptional regulation was demonstrated in mice with a germ
line deletion of the TNF- 3UTR ARE. Macrophages and T
cells from these mice produced 3- to 10-fold more TNF-
protein than their wild-type counterparts, and the animals
spontaneously developed pathologies indistinguishable from
rheumatoid arthritis and Crohn’s disease (15).
Utilizing a novel screen for TNF- 3UTR binding pro-
teins, we identified calcium-regulated heat stable protein 1
(CARHSP1, also called CRHSP24) as specifically interacting with
the 3UTR of TNF-. CARHSP1 contains a cold-shock do-
main with two RNA binding motifs (20, 23); cold-shock do-
mains preferentially bind polypyrimidine regions of single-
stranded RNA and DNA and regulate ribosomal translation,
mRNA degradation, and the rate of transcription termination.
To date, there is limited information regarding CARHSP1,
with the published literature focusing primarily on the sig-
naling pathways that phosphorylate and dephosphorylate
CARHSP1 (2, 13, 17, 23, 27). These reports demonstrate that
CARHSP1 is phosphorylated through the p85 phosphatidyl ino-
sitol 3-kinase (PI3K)-Akt signaling axis on Ser-53 (23). The kinase
DYRK2 has also been shown to phosphorylate CARHSP1
on Ser-30, -32, and -42 in vitro (27). Dephosphorylation of
CARHSP1 is induced by cAMP, and this process is inhibited by
cyclosporine, FK506, okadaic acid, fostriecin, and calyculin A.
Together, these data implicate CARHSP1 as a target of protein
* Corresponding author. Mailing address: VA Medical Center, Re-
search 151, 215 North Main St., White River Junction, VT 05009.
Phone: (802) 295-9363, ext. 5616. Fax: (802) 296-6308. E-mail: seth
.brooks@dartmouth.edu.
† Present address: Case Western Reserve University, Department of
Pathology, Cleveland, OH 44106.
§ Supplemental material for this article may be found at http://mcb
.asm.org/.
 Published ahead of print on 15 November 2010.
277
phosphatase 2A (PP2A) and calcineurin (PP3) for dephosphor-
ylation (2, 13).
Having identified CARHSP1 as a TNF- 3UTR-interacting
protein, we generated stably expressing control and CARHSP1
short-hairpin RNA (shRNA) in RAW264.7 cells, a widely em-
ployed mouse macrophage cell line, to examine the effect of
CARHSP1 knockdown on TNF- mRNA and protein. These
data demonstrate that the loss of CARHSP1 inhibits TNF-
protein production and reduces the level of TNF- mRNA.
mRNA stability assays with the same cell lines demonstrate
that the loss of CARHSP1 decreases the TNF- mRNA half-
life in LPS-stimulated cells from a half-time (t1/2) of 49 min to
a t1/2 of 22 min in RAW264.7 cells and decreases the stability
in resting cells from a t1/2 of 29 min to a t1/2 of 24. Next, we
examined the effect of CARHSP1 overexpression in a tran-
sient-transfection system using TNF- 3UTR luciferase re-
porters in RAW264.7 cells. CARHSP1 overexpression in-
creases in TNF 3UTR luciferase production in resting wild-
type RAW264.7 cells but not in LPS-stimulated cells.
Performing the same experiments in CARHSP1 shRNA
RAW264.7 cells demonstrates that transfected CARHSP1 sig-
nificantly increases TNF- 3UTR luciferase production in LPS-
stimulated cells. The effect seen in resting cells is lost if the
TNF- ARE is deleted from the 3UTR. Further overexpres-
sion studies establish that inhibition of either calcineurin or
Akt but not PP2A abolishes the increase in TNF 3UTR lucif-
erase expression seen with CARHSP1 overexpression. Finally,
subcellular analysis of CARHSP1 demonstrates that it is a
cytoplasmic protein that localizes to processing bodies and
exosome granules but is not present on translating mRNAs.
Together these data establish CARHSP1 as a TNF- mRNA
stability enhancer that is critical for TNF- mRNA stabiliza-
tion.
MATERIALS AND METHODS
Materials. LPS (Escherichia coli O26:B6), FK-506, and dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich. Triciribine was purchased from
Biomol; okadaic acid was purchased from Enzo. The following antibodies were
purchased: CARHPS1 (Abcam), tubulin (Sigma), p84 (Abcam), Rrp44 (Abcam),
Rrp45 (GenWay), eIF2 (StressGen), Ge-1 (Santa Cruz Bio), 4E-T (Santa Cruz
Bio), and pan-actin (Neo-Markers); the anti-TTP antibody was a generous gift of
William Rigby.
RNA capture assay. 293 cells (5  106) were plated in 150-mm tissue culture
plates and transfected with 20 g of the luciferase reporter construct pGL3-C or
pGL3-TNF 3UTR using Lipofectamine 2000. Twenty-four hours later, the cells
were collected, washed twice in 4°C phosphate-buffered saline (PBS), resus-
pended in 500 l of capture buffer (10 mM HEPES, 10 mM KCl, 1 mM EDTA,
1 mM EGTA, 1 mM MgCl2, 1 mM dithiothreitol [DTT], 5% glycerol, 1.0 mM
sodium orthovanadate, 10 l/ml Halt protease inhibitor [Pierce, Rockford, IL],
and 500 U RNase inhibitor Invitrogen, Carlsbad, CA]), and incubated on ice for
10 min. NP-40 was added to a final concentration of 0.25%, and the cells were
pipetted up and down 20 times to lyse them, following which the nuclei were spun
out at 1,500  g for 10 min at 4°C and the supernatant was used for the binding
assay.
In vitro-transcribed antisense RNA was generated using the MEGAshortscript
kit (Ambion) according to the manufacturer’s protocol to generate a 43-nucle-
otide (nt) biotinylated antisense RNA complementary to the luciferase coding
region and containing no predicted secondary structure at 37°C (6). The primers
used to generate partially single-stranded oligonucleotides employed for in vitro
transcription were the T7 primer (AATTTAATACGACTCACTATAGG) and
the Luc primer (GTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTTTC
TGAGGCCTATAGTGAGTCGTATTAAATT).
For the binding reaction, 5 mg of supernatant was incubated with 100 g of
antisense RNA at 37°C for 1 h with continuous rotation. Twenty microliters
packed streptavidin agarose, washed three times with capture buffer, was added
to the binding reaction mixture for 30 min at 37°C with continuous rotation,
following which the beads were pelleted and washed three times with capture
buffer, and proteins were eluted with 200 l of rehydration buffer (7 M urea, 2
M thiourea, 1% [wt/vol] ASB-14 detergent, 40 mM Tris base, 0.001% bromo-
phenol blue). The protein samples were then used for two-dimensional (2D)
PAGE to identify potentially relevant proteins for further analysis.
Two-dimensional gels were run using an 11-cm pH 3 to 10 immobilized pH
gradient (IPG) strip (Bio-Rad, Hercules, CA) and 8 to 16% acrylamide Criterion
precast gels (Bio-Rad), according to the manufacturer’s specification. Following
the runs, gels were stained with SilverQuest (Invitrogen) reversible silver stain
according to the manufacturer’s protocol, scanned with the Bio-Rad GS-800
quantitative scanner, and analyzed using the PDQuest 2D analysis software
program to identify the presence or absence of proteins under different condi-
tions. Proteins of interest were excised, subjected to in-gel tryptic digestion, and
run in tandem mass spectrometry at the Dartmouth Proteomics Core, and spec-
tra were analyzed using the Mascot analysis software program.
Immunoblotting. Cytoplasmic and nuclear fractions were generated as previ-
ously described (7). Cytoplasmic and nuclear lysates was resolved by 8-to-16%-
gradient SDS-PAGE, electrotransferred to nitrocellulose, and immunoblotted
with the indicated antibodies according to the manufacturer’s protocol.
Generation of stable shRNA-expressing RAW264.7 cells. CARHSP1 and non-
target control shRNA plasmid constructs were purchased from Sigma-Aldrich.
shRNA plasmid constructs were transfected into RAW264.7 cells using Amaxa
nucleofection in accordance with the manufacturer’s instructions (Lonza Walker-
rsville Inc.). Transfected cells were incubated in standard RAW264.7 medium for
24 h and were thereafter maintained under selective pressure in RAW264.7
medium supplemented with 6 g/ml puromycin. Clones positive for CARHSP1
knockdown were identified 2 weeks posttransfection by Western blotting for
CARHSP1. Promising clones were then successively refined by two additional
rounds of limiting dilution and screening by Western blotting. Nontarget control
shRNA-expressing RAW264.7 cells were not cloned; rather, they were main-
tained as a mixed population selected based on their resistance to 6 g/ml
puromycin.
Quantification of CARHSP1 knockdown. For each Western blot, images of
CARHSP1 and actin bands were captured using a gel imaging station (Versa-
Doc; Bio-Rad). Analysis of the images was performed using the ImageJ software
program as previously described (11). Briefly, images were background sub-
tracted using a rolling ball size of 50 pixels, and then the intensity of the
CARHSP1 and actin bands was determined using ImageJ’s gel analysis routine.
A normalized intensity for each CARHSP1 band was calculated by dividing the
CARHSP1 intensity by the actin intensity. Relative intensity for a given exper-
imental condition was calculated by dividing the actin normalized intensity by the
actin normalized intensity for the control condition.
Luciferase vectors. pGL3-Control (Promega) is the backbone vector. First, the
intron from the 5UTR of pRL-SV40 was amplified by PCR and clones into the
5UTR of pGL3-Control-Intron, which was cut with AvrII and HindIII. pGL3-
TNF 3UTR-Intron contains the complete mouse TNF 3UTR: nucleotides 865
to 1619 cloned into the XbaI site in the pGL3-Control-Intron vector. pGL3-
ARE-Del-Intron contains TNF 3UTR nucleotides 865 to 1283 and 1354 to 1619,
generated using Quikchange (Stratagene) and the pGL3-TNF-3UTR-Intron
vector.
Transient transfections and luciferase assays. RAW 264.7 cell transfections
were performed in triplicate at least 5 times (n  5) using Lipofectamine LTX
according to the manufacturer’s protocol for RAW264.7 cells. Briefly, 125,000
RAW cells were plated in 24-well plates and allowed to rest for 24 h. Five
hundred nanograms of luciferase construct and the indicated amount of mouse
CARHSP1 expression vector (accession no. NM_025821; nucleotides 49 to 495)
or backbone pcDNA 3.1His C vector were use for each well. Cells were lysed 24 h
after transfection, and luciferase values were quantified. For each experiment,
luciferase values for TNF 3UTR luciferase expression were normalized to the
effect on control luciferase expression for the specific condition. The resulting
TNF-3UTR-Intron luciferase values were expressed as a percentage of the
luciferase expression with no treatment (luciferase value for condition X/lucif-
erase value with no treatment).
mRNA quantification and stability assays. Treatment groups are indicated in
the text. For RNA stability assays, actinomycin D (ActD) (5 g/ml) was added to
inhibit transcription and RNA was isolated at either 0, 30, and 60 min after ActD
administration or 0, 15, and 30 min after ActD administration. Total RNA was
isolated using the RNAEasy minikit with on-column DNase digestions (Qiagen)
and quantified by spectrophotometry. Reverse transcription was performed using
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) on DNase-
treated total RNA and oligo(dT) according to the manufacturer’s protocol.
Quatitative PCR was performed as previously described using the Sybr green
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PCR core kit (Applied Biosystems, Foster City, CA) and a three-step reaction:
94°C for 30 s, 55°C for 30 s, and 72°C for 30 s (19). Mouse TNF primers were
previously described (9); mouse cyclophilin primers were purchased from Su-
perarray. The mRNA half-life was calculated from the linear regression of the
curve generated by plotting the log10 [TNF-] as a function of actinomycin D
treatment.
Sucrose density fractionation. For continuous sucrose gradient fractionation,
cells were washed three times with 1 PBS and resuspended in 500 l of the lysis
buffer polybuffer (15 mM Tris-HCl [pH 7.4], 15 mM MgCl2, 0.3 M NaCl, 1%
Triton X-100, 0.1% [vol/vol] 2-mercaptoethanol). Cells were lysed by 20 strokes
with a Teflon pestle homogenizer at 1,500 rpm and centrifuged at 12,000  g for
10 min to pellet the nuclei. Postnuclear supernatant was loaded onto the top of
5 ml of a 5 to 45% continuous sucrose gradient, and the samples were centrifuged
at 4°C for 2 h at 55,000 rpm in a SW55Ti rotor (Beckman). Fractions were
collected manually in 500-ml aliquots, and the pellet was resuspended in 500 ml.
For the 30% sucrose cushion fractionation, the above procedure was employed
with a 30% sucrose replacing the 5 to 45% gradient and an equal volume of
supernatant to cushion was used.
Immunocytochemistry. RAW264.7 cell immunocytochemistry was performed
according to the protocol of Kedersha and Anderson (14). Processing body
markers were the following: goat anti-4E-T (1:200) and mouse anti-GE-1/hedls
(1:1,000). Exosome markers were the following: mouse anti-Rrp44 (1:200), rab-
bit anti-Rrp45 (1:500), chicken anti-CARHSP1 (1:200), and mouse anti-Xpress
(1:200). The following donkey Fab fragment secondary antibodies were pur-
chased from Jackson Research: Cy2-chicken (1:200), Cy3-goat (1:2,000), and
Cy-5–mouse or -rabbit (1:200) antibody. Images were obtained using a Nikon
Eclipse 80i microscope with a 60 oil objective and analyzed using the NIS-
Elements BR 3.0 software program.
RESULTS
RNA capture assay. One of the limitations in the field of
posttranscriptional regulation has been the inability to system-
atically identify proteins that interact with the 3UTR of an
intact, capped, polyadenylated mRNA transcript that has been
exported from the nucleus. Utilizing the transfection of lucif-
erase reporter vectors, we have developed an assay to capture
luciferase messages containing different 3UTRs with their as-
sociated proteins. The use of transfected vectors allows for
high levels of mRNA expression as well as the use of a com-
mon biotinylated antisense RNA probe to capture the message
and its associated proteins for all luciferase vectors. Transfect-
ing cells with either the control or experimental luciferase
vectors allows for identification of 3UTR-specific interacting
proteins, in this case those that interact with the TNF-
3UTR, while excluding proteins that interact with the control
luciferase message (Fig. 1).
Identification of CARHSP1. Utilizing the RNA capture
assay, we identified CARHSP1 as a TNF- 3UTR-interact-
ing protein. Tandem mass spectrophotometry identified a
78% overlap between peptide fragments of the gel spot and
CARHSP1 (Fig. 2A). CARHSP1 contains a cold-shock do-
main, allowing it to bind single-stranded RNA or DNA (8,
9), indicated in Fig. 2B. The mouse and human proteins are
96.6% homologous over 148 amino acid residues. Our first
questions regarding a role of CARHSP1 in TNF- posttran-
scriptional regulation related to its subcellular distribution and
expression pattern in macrophages. Western blotting (Fig. 2C)
demonstrates that CARHSP1 is confined to the cytoplasm and
its expression is not altered by LPS activation of RAW264.7
cells (100 ng/ml).
Effect of CARHSP1 knockdown in RAW264.7 cells. To begin
to functionally characterize the role of CARHSP1 in TNF-
expression, we generated several stable CARHSP1 shRNA-
expressing RAW264.7 cell lines. Figure 3A shows the level of
CARHSP1 protein knockdown in six different RAW cell lines
as well as the control shRNA cells; CARHSP1 shRNA clones
1A4 and 2F2 were employed for further analysis. Quantitative
densitometry of three Western blots using samples isolated on
three separate days reveals a 74% reduction in CARHSP1
protein levels in clone 1A4 and a 70% reduction in CARHSP1
protein levels in clone 2F2. CARHSP1 protein knockdown by
shRNA results in a significant decrease in TNF- protein
present in the culture supernatant following LPS stimulation
(P  0.005 at 1, 2, and 4 h), as determined by enzyme-linked
immunosorbent assay (ELISA) (Fig. 3B). TNF- expression
from control shRNA and that from wild-type RAW264.7 cells
are nearly identical (see Fig. S1 in the supplemental material);
as with wild-type RAW264.7 cells, TNF- protein levels from
both control and CARHSP1 shRNA cells were below the level
of detection in unstimulated cells. TNF- mRNA levels were
also examined in the control cells and the two CARHPS1
shRNA clones (Fig. 3C). For these studies, we employed cy-
clophilin as a loading control; our tests reveal that cyclophilin
expression changes by less than 5% over the 4-h LPS stimula-
tion time course. The cyclophilin primers have an efficiency of
95.7%, while the TNF- primers have an efficiency of 97.8%,
using 50 ng of starting total RNA per reaction well in 25-l
quantitative PCRs (qPCRs). LPS stimulation of the control
shRNA cells results in a dramatic increase in TNF- mRNA
FIG. 1. RNA capture assay. (A) Schematic of the captured Control
and TNF-3UTR luciferase mRNA and the individual 2-dimensional
gels. (B) Overlap of representative control luciferase (red) and TNF-
3UTR luciferase (green) RNA capture gels.
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levels, peaking at about 2 h and then beginning to decline. In
contrast, TNF- mRNA levels are significantly reduced in the
CARHSP1 shRNA clones (P  0.02 at 2 and 4 h LPS). Thus,
loss of CARHSP1 reduces both TNF- mRNA and protein
levels in RAW264.7 macrophages, implying that CARHSP1
regulates the stability of the TNF- message rather than reg-
ulating TNF- translation, which should alter protein but not
message levels.
CARHSP1 stabilizes TNF- mRNA. To confirm that
CARHSP1 regulates TNF- mRNA stability, we performed
stability assays using the control shRNA cells and CARHSP1
shRNA clone 2F2. The TNF-mRNA half-life following 2 h of
LPS stimulation is 49 min in the control shRNA cells and 22
min in the CARHSP1 shRNA cells. At both the 30-min time
point and the 60-min time point, the remaining TNF- mes-
sage in the CARHSP1 shRNA cells is significantly reduced
compared to that in the control shRNA cells (P 0.01). Initial
studies with RNA isolated from unstimulated clone 2F2 cells
provided too little TNF- mRNA to quantify over the time
course of the stability assay. In order to obtain sufficient signal,
the reaction volume for the qPCRs was increased to 50 l and
250 ng of starting total RNA was used per well. This increased
the signal sufficiently to perform stability assays; however, we
did not observe a difference in TNF-mRNA stability between
the control shRNA and CARHSP1 shRNA cells. Interestingly,
more TNF- mRNA was present in the control shRNA cells
FIG. 2. CARHSP1 was identified in a screen for TNF 3UTR-
interacting proteins. (A) Tandem mass spectrometry of a putative TNF
3UTR-interacting protein identified by 2D gel electrophoresis re-
sulted in a 78% overlap with CARHSP1, bold sequence. (B) Mouse
and human CARHSP1 share 96.6% identify over 148 residues. The
bold areas indicate the cold-shock domain; the underlined areas are
the predicted RNA binding domains. (C) Time course of CARHSP1
expression in resting and LPS-stimulated RAW264.7 cells. Western
blotting for CARHSP1 demonstrates localization to the cytoplasm but
not the nucleus. Tubulin (Tub) serves as a cytoplasmic loading control,
while the nuclear matrix protein p84 serves as a nuclear loading con-
trol.
FIG. 3. CARHSP1 knockdown reduces TNF- protein expres-
sion and mRNA levels. (A) Using either a control or a CARHSP1
shRNA, stable shRNA-expressing RAW264.7 cells were generated.
Six shRNA CARHSP1 clones were screened by Western blotting for
altered CARHSP1 expression. Densitometric quantification of
three separate Western blots with 3 biologic replicates demon-
strates CARHSP1 knockdown of 70 to 74% for the six clones.
(B) Knockdown of CARHSP1 protein expression, clones 14A and
2F2, results in a significant decrease (P  0.005) in TNF- protein
released into the supernatant at 1, 2, and 4 h post-LPS addition
compared with control shRNA cell TNF- expression, as deter-
mined by ELISA. (C) TNF- mRNA levels are significantly reduced
in CARHSP1 shRNA RAW264.7 cells compared with those in
control shRNA RAW264.7 cells at 2 and 4 h of LPS stimulation
(P  0.02), as quantified by quantitative PCR.
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than in the CARHSP1 shRNA cells at time zero of the stability
assay (data not shown).
The lack of an effect of CARHSP1 knockdown on TNF-
mRNA stability in resting cells but difference in basal TNF-
mRNA levels is somewhat paradoxical, particularly given the
cytoplasmic localization of CARHSP1, which presumably pre-
cludes the protein from functioning as a transcription factor.
Given the extremely low levels of TNF- mRNA in resting
cells and the restriction of CARHSP1 to the cytoplasm, we
postulated that the pool of TNF- RNA in the nucleus might
make the TNF- mRNA appear more stable in the CARHSP1
shRNA cells, since stability assays utilize the percent remain-
ing message. To test this, we fractionated resting control and
CARHSP1 shRNA cells into cytoplasmic and nuclear com-
partments and compared the amount of RNA present in each
fraction (Fig. 4B). The effectiveness of fractionation is dem-
onstrated in Fig. 2C. The amounts of TNF- RNA present
in the nuclei of control and CARHSP1 shRNA cells are
nearly identical (5.98 amol in control cells and 6.13 amol in
CARHSP1 cells). In contrast, there is significantly more TNF-
mRNA in the cytoplasm of control cells (4.25 amol) than in
CARHSP1 shRNA cells (2.58 amol) (P  0.02). For these ex-
periments, equal total starting RNA was employed; thus, these
data do not indicate the precise cellular ratio of cytoplasmic to
nuclear TNF- message. However, we can conclude that the
nuclear fraction of TNF- message is not trivial and the con-
tribution of the nuclear TNF- RNA to the apparent half-life
of the TNF- message is greater in CARHSP1 shRNA cells,
likely making the message appear more stable. This effect is
likely less relevant in the LPS-stimulated cells due to the large
increase in TNF- mRNA, the inhibition of TNF- mRNA
decay pathways, and changes in the export of the TNF- mes-
sage from the nucleus (10, 24).
To confirm these findings, we performed stability assays
with control and CARHSP1 shRNA cells, using RNA iso-
lated from the cytoplasmic fraction. For the cytoplasmic
stability studies, the time course was shortened to 30 min
from 60 min to ensure sufficient TNF- message was present
to quantify. Cytoplasmic TNF- mRNA half-life in the Con-
trol shRNA cells was 29 min, while the cytoplasmic TNF-
mRNA half life in the CARHSP1 shRNA cells was 24 min.
There was significantly less remaining TNF- mRNA at both the
15-min and 30-min time points (P  0.05). Together, these data
demonstrate that CARHSP1 regulates TNF- mRNA stability
in both resting and LPS-stimulated macrophages.
Overexpression of CARHSP1 in RAW264.7 cells. Next, we
cloned the full-length coding region of mouse CARHPS1 into
an expression vector and performed transient transfections
utilizing a well-established system that we have previously em-
ployed in a number of studies to examine the regulation of
TNF- by tristetraprolin (TTP) (6, 7, 9, 22, 24). To establish
the optimal concentration of the CARHSP1 expression con-
struct, initial studies employed either pGL3-Control-Intron or
pGL3-TNF-3UTR-Intron luciferase reporter constructs (24)
and increasing amounts of the CARHSP1 expression vector.
Figure 5A demonstrates that increasing amounts of CARHSP1
have no effect on luciferase expression from the control vector
in either resting or LPS-stimulated RAW264.7 cells. Figure 5B
shows the effect of increasing CARHSP1 expression on TNF
3UTR luciferase expression. In resting RAW264.7 cells, there
is a dose-dependent increase in TNF 3UTR luciferase expres-
sion, with a maximal and statistically significant effect at 100 ng
(P  0.01). The 27% increase in TNF 3UTR luciferase ex-
pression is physiologically comparable to the change in TNF
3UTR luciferase expression seen with the TNF mRNA sta-
bility regulator TTP (9), one of the best-characterized post-
transcriptional regulators.
In contrast to the results seen in resting RAW264.7 cells,
overexpression of CARHSP1 followed by LPS stimulation (2 h,
100 ng/ml) results in a nonsignificant decrease (9%) in TNF
3UTR luciferase expression. Figure 5C shows CARHSP1 in
RAW264.7 cells transfected with 100 ng of CARHSP1 expres-
sion vector; pcDNA3.1 HisC encodes a His and Xpress epitope
at the amino end of the protein which adds about 6 kDa to the
protein. Figure 5D demonstrates that the TNF- ARE is re-
quired for the CARHSP1 cotransfection effect. The increase
FIG. 4. CARHSP1 knockdown reduces TNF- mRNA stability. mRNA stability assays were performed in resting and LPS-stimulated control
and clone 2F2 shRNA RAW264.7 cells. mRNA was isolated at the indicated time points following the addition of the transcriptional inhibitor
ActD (5 g/ml). (A) Knockdown of CARHSP1 results in a decrease in TNF- mRNA half life from t1/2  49 min to t1/2  22 min following 2 h
of LPS treatment, with a significant reduction in the percentage of remaining TNF- mRNA at 30 min and 60 min (P  0.01). (B) Fractionation
of control and CARHSP1 shRNA cells into cytoplasmic and nuclear compartments and quantification of TNF- mRNA levels in each. Nuclear
fractions have almost identical TNF-mRNA levels, while TNF- levels are significantly reduced in the cytoplasm of CARHSP1 shRNA cells (P
0.02). (C) Knockdown of CARHSP1 results in a decrease in the TNF- mRNA half-life from t1/2  29 min to t1/2  24 min in the cytoplasmic
fraction of resting cells, with a significant reduction in the percentage of remaining TNF- mRNA at 15 min and 30 min (P  0.05).
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seen in TNF 3UTR expression in resting RAW264.7 cells with
100 ng of CARHSP1 is absent when the TNF-ARE-Del-Intron
luciferase vector, which lacks the TNF- ARE, is employed,
demonstrating that CARHSP1 posttranscriptional regulation
requires the TNF- ARE.
It is possible that in the context of LPS stimulation, when the
TNF- mRNA degradation pathways are inhibited, there is
sufficient CARHSP1 protein present in RAW264.7 cells to act
on the TNF- mRNA, making the transfected protein super-
fluous. To test this, we performed the transfection studies with
the CARHSP1 shRNA clone 1B5, again using 100 ng of either
CARHSP1 expression vector or pcDNA3.1 HisC backbone. It
is important to note that the CARHSP1 shRNA targets the
3UTR of CARHSP1; the CARHSP1 expression vector lacks
the CARHSP1 3UTR, preventing shRNA targeting of the
mRNA generated from the vector. In resting CARHSP1
shRNA cells (Fig. 6A), CARHSP1 transfection significantly
increased TNF- 3UTR-mediated luciferase expression rela-
tive to that of the pcDNA3.1 HisC-transfected CARHSP1
shRNA cells (P  0.005). The effect of transfected CARHSP1
in the CARHSP1 shRNA cells was significantly higher than
that in the wild-type RAW cells (P  0.01). In LPS-stimulated
CARHSP1 shRNA RAW264.7 cells, CARHSP1 transfection
results in a significant (P  0.01) 39% increase in TNF-
3UTR luciferase expression. These findings support the hy-
pothesis that there is sufficient CARHSP1 in wild-type cell to
stabilize the TNF- mRNA in the context of LPS stimulation,
and they support the findings from Fig. 3 and 4.
Signaling control of CARHSP1 function. Having established
that CARHSP1 overexpression enhances TNF 3UTR lucifer-
ase expression, we next sought to establish the signaling path-
ways involved in modulating CARHSP1 function. Dephos-
phorylation of CARHSP1 is induced by cAMP, and this
process is inhibited by cyclosporine, FK506, okadaic acid,
fostriecin, and calyculin A; together, these data implicate
CARHSP1 as a target of calcineurin (PP3) and PP2A for dephos-
phorylation (2, 13). The same group also demonstrated that
CARHSP1 is phosphorylated at serine 53 by the PI3K-Akt
pathway (2). In light of these data, we examined the effect of
the calcineurin inhibitor FK506 (1 ng/ml), the PP2A inhibitor
okadaic acid (10 nM), and the Akt inhibitor triciribine (1 M)
on CARHSP1 function with regard to TNF 3UTR luciferase
expression. Figure 6B shows the effect of inhibiting calcineurin,
PP2A, and Akt for 135 min total in wild-type RAW264.7 cells,
presented to demonstrate the specific effect of inhibition on
CARHSP1 function. Okadaic acid treatment (PP2A inhibi-
tion) does not alter the CARHSP1-mediated increase in
TNF- 3UTR luciferase expression, which remained signifi-
cantly higher (P  0.02). In contrast, inhibition of either cal-
cineurin (FK-506) or Akt (triciribine) blocks the increase in
TNF-3UTR luciferase expression with CARHSP1 cotransfec-
tion.
The same experiment was performed with 2 h of LPS
stimulation; cells were treated with drug or DMSO for 15
min, followed by the addition of LPS for 2 h (135 min of
total drug treatment) (Fig. 6C). No significant effect on
CARHSP1 function was observed with drug treatment in the
context of LPS stimulation, consistent with the lack of effect
seen with CARHSP1 transfection and LPS stimulation, as shown
in Fig. 5B. The experiment shown in Fig. 6C was then performed
using CARHSP1 shRNA cells (Fig. 6D). These data demon-
strate that in the context of LPS stimulation, transfected
CARHSP1 function is inhibited by FK-506 and triciribine, as it
is in resting cells.
Subcellular localization of CARHSP1. In light of the post-
transcriptional effect of CARHSP1, we sought to determine
the subcellular distribution of the protein. Sucrose density frac-
tionation (5 to 45%) of resting and LPS-activated RAW264.7
cell cytoplasm demonstrates that CARHSP1 is present in the
light fractions, 0 to 10% sucrose (Fig. 7). In contrast, the
TNF- mRNA-destabilizing protein TTP is present through
the entire gradient and pellet (22); please note that TTP levels
in resting cells are low. Quantification of the RNA concentra-
tion in each fraction is presented in Fig. S2A in the supple-
mental material. These data demonstrate that the CARHSP1
FIG. 5. The effect of CARHSP1 overexpression on TNF 3UTR-
mediated luciferase expression. Mouse CARHSP was cloned into
pcDNA3.1 His-C and used for transfections into RAW264.7 cells with
different luciferase reporter vectors. (A) Effect of increasing CAR-
HSP1 transfection on pGL3-Control-Intron luciferase expression in
resting and LPS-stimulated (2 h) RAW264.7 cells. There is no signif-
icant effect of CARHSP1 transfection on control luciferase expression.
(B) Effect of increasing CARHSP1 transfection on pGL3-TNF
3UTR-Intron luciferase expression in resting and LPS-stimulated (2
h) RAW264.7 cells. One hundred nanograms of transfected CAR-
HSP1 has the maximal effect at the lowest dose, resulting in a signif-
icant increase (P  0.01) in TNF 3UTR luciferase expression in
resting cells. There was no effect of transfected CARHSP1 in LPS-
stimulated cells. (C) Expression of 100 ng of recombinant CARHSP1
in RAW264.7 cells. Top panel, Western blot of RAW264.7 cells trans-
fected with either pcDNA3.1 His-C or CARHSP1 pcDNA3.1 His-C
blotted for CARHSP. Middle panel, Western blot identical to that in
the top panel, blotted for the Xpress epitope tag encoded by
pcDNA3.1 His-C. Bottom panel, middle panel membrane blotted for
actin as a loading control. (D) Effect of 100 ng of CARHSP transfec-
tion on pGL3-ARE-Del-Intron luciferase expression. No significant
effect of CARHSP1 transfection was seen on ARE-Del luciferase
expression in either resting or LPS-stimulated RAW264.7 cells.
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protein does not dramatically shift its subcellular distribution
in response to LPS. These data also confirm findings, shown in
Fig. 2, that CARHSP1 protein levels do not change dramati-
cally with LPS stimulation, again in contrast to TTP. To further
clarify these data, we partitioned cytoplasmic lysate through a
30% sucrose cushion and quantified the amount of CARHSP1
protein in the pellet and supernatant (see Fig. S2B in the
supplemental material). These data demonstrate that all
CARHSP1 signal is present in the non-polysome-containing
supernatant.
Next, we sought to determine if CARHSP1 is present in
processing bodies (P-bodies). P-bodies are cytoplasmic foci
containing translationally repressed mRNA; messages within
P-bodies can be degraded in a 5-to-3 manner or stored for a
return to translation (21). P-bodies lack translation factors,
with the exception of eIF4E. Given the cross-reactivity of the
CARHSP1 antibody seen in Fig. 2, we first established
CARHSP1 immunocytochemical distribution by comparing
the CARHSP1-specific antibody with the distribution of trans-
fected CARHSP1, utilizing the Xpress tag. Figure 8A estab-
lishes that both wild-type and transfected CARHSP1 colocal-
izes in distinct foci in RAW264.7 cells. White arrows indicate
overlapping signal; given the preponderance of overlapping
signal in granules, we concluded that granules reacting with the
CARHSP1 represent authentic CARHPS1 and not a cross-
reactive protein.
To determine if CARHSP1 localizes to P-bodies, we em-
ployed the P-body markers 4E-T, which inhibits translation by
sequestering the CAP binding protein eIF4E, and the en-
hancer of decapping protein Ge-1/Helds1 (14). Since macro-
phages express Fc receptors, we employed Fab fragment sec-
ondary antibodies. These studies demonstrate that CARHSP1
colocalizes with the P-body components in both resting (Fig.
8B) and LPS-stimulated (2 h) (Fig. 8C) cells. While a subset of
the granules contain all three proteins in both resting and
LPS-stimulated RAW264.7 cells, there are also granules of
each protein present that do not appear to overlap with the
other proteins examined. Whether the other proteins are part
of the granule that is outside of the field of focus or the
proteins are present in distinct subsets of granules is unclear.
FIG. 6. The effects of calcineurin, PP2A, or AKT inhibition on CARHSP1 function. RAW264.7 cells were transfected with either pGL3-
Control-Intron or pGL3-TNF-3UTR-Intron and either 100 ng of CARHSP1 expression vector or pcDNA3.1 HIS-C. (A) Transfection of
CARHSP1 shRNA clone 1B4 cells with and without LPS stimulation (2 h). Transfected CARHSP1 mediates a significant increase in TNF-
3UTR luciferase expression in both resting and LPS-stimulated cells (P  0.01). (B) Wild-type cells were treated for 135 min total with DMSO
(vehicle), FK506 (1 ng/ml), okadaic acid (10 nM), or triciribine (1 M). TNF 3UTR luciferase expression is normalized to the treatment effect
on comparable control luciferase expression and graphed to demonstrate the effect of inhibition on CARHSP1 function. CARHSP1 transfection
resulted in a significant increase in TNF 3UTR luciferase expression with either DMSO or okadaic acid treatment (P  0.012). The effect of
CARHSP1 transfection is lost with FK506 and triciribine treatment. (C) Cells were treated for 15 min with DMSO (vehicle), FK506 (1 ng/ml),
okadeic acid (10 nM), or triciribine (1 M), following which LPS was added for 2 h. There were no significant effects. (D) The experiment in panel
C was performed using CARHSP1 shRNA clone 1B4. The effect of CARHSP1 transfection was lost with FK506 and triciribine treatment.
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We also examined the localization of CARHSP1 with exo-
some granules, which are foci of exosomes degrading mRNA
in a 3-to-5 manner. Figure 9A shows that CARHPS1 colo-
calizes with the structural exosome component Rrp45 as well
as the cytoplasmic exosome RNase Rrp44 in resting cells. Fig-
ure 9B demonstrates the same finding in RAW 264.7 cells
stimulated with LPS for 2 h. We have previously demonstrated
that the P-body 5-to-3 RNase Xrn1 colocalizes with the exo-
some 3-to-5 RNase Rrp44 in HeLa cells (5). Given that
CARHSP1 colocalizes with both P-bodies and exosome, we
were interested in examining if CARHPS may link these two
structures. After examining a number of cells in both resting
and LPS-stimulated RAW264.7 cells, we did not find colocal-
ization of CARHSP1 with both Ge-1 and Rrp45. We did,
however, find colocalization of Ge-1 with Rrp45 in both resting
(Fig. 9C) and LPS-stimulated (Fig. 9D) cells. Thus, while we
cannot rule out that CARHSP1 localizes to a subset of P-body/
exosome complexes, the data establish the existence of P-body/
exosome complexes.
DISCUSSION
Utilizing a screen for TNF- mRNA-interacting proteins,
we identified CARHSP1 as a posttranscriptional regulator of
TNF- production specifically acting to stabilize the TNF-
message. shRNA-mediated knockdown of CARHSP1 signifi-
cantly reduces TNF- mRNA levels and protein production in
RAW264.7 cells stimulated with LPS (Fig. 3), as well as TNF-
mRNA levels in resting cells (Fig. 4). TNF- mRNA stability
assays with one of the CARHSP1 shRNA clones demonstrate
that the loss of CARHSP1 results in a significant reduction in
the TNF- mRNA half-life in both resting and LPS-stimulated
RAW264.7 macrophages (Fig. 4). These data establish that
CARHSP1 is required to maintain basal TNF- messages lev-
els and to fully stabilize the TNF- message in macrophages in
response to LPS stimulation. Supporting the shRNA findings,
overexpression of CARHSP1 results in a significant increase in
TNF- 3UTR luciferase production in resting cells, where the
additional CARHSP1 protein acts to increase TNF- mRNA
half-life (Fig. 3). Thus, in resting cells, CARHSP1 overexpres-
sion operates to counter the dominance of the TNF- mRNA
decay pathways. Overexpression of CARHSP1 in LPS-stimu-
lated cells, when the regulated TNF- mRNA decay pathways
are inhibited, does not produce a significant increase in TNF-
3UTR luciferase production (Fig. 5). However, when the
same studies are performed in CARHSP1 shRNA macro-
phages, CARHSP1 overexpression results in a significant in-
crease in TNF- 3UTR luciferase production in LPS-stimu-
lated cells and further enhances TNF- 3UTR luciferase
production in resting cells (Fig. 6). The finding that CARHSP1
FIG. 7. CARHSP1 does not associate with actively translating
mRNA. Cytoplasm from resting and LPS-stimulated RAW264.7 cells
was fractionated over a continuous 5 to 45% sucrose gradient, and
500-l aliquots were collected. Fractionated cytoplasm from 0-, 1-, 2-,
or 4-h LPS-stimulated RAW264.7 cells was blotted for CARHSP1,
which is present in the two lightest fractions. Following CARHSP1
blotting, the membranes were stripped and blotted for TTP. As pre-
viously reported, TTP levels increase with LPS stimulation and TTP is
present thought the gradient, demonstrating fractionation.
FIG. 8. CARHSP1 localizes to processing bodies. (A) Immnocyto-
chemistry of total and transfected CARHSP1. Transfected Xpress-
tagged CARHSP1 is shown in red; total CARHSP1 is shown in green.
(B) CARHSP1 (green) colocalizes with the processing body markers
4E-T (red) and Ge-1 (blue) in resting RAW284.7 cells. The boxes in
the center are an enlargement of the white square in the flanking
panel. Note that the Ge-1 antibody cross-reacts with nuclear S6 kinase,
resulting in a strong nuclear signal. (C) CARHSP1 (green) colocalizes
with the processing body markers 4E-T (red) and Ge-1 (blue) in
LPS-stimulated (2 h) RAW284.7 cells.
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protein levels are not altered by LPS stimulation (Fig. 2 and 7)
supports the conclusion that there is sufficient endogenous
protein to fully stabilize the TNF- message in LPS-stimulated
RAW264.7 cells. Together, these findings support the conclu-
sion that in macrophages, the half-life of TNF- mRNA is
determined by the activities of both degradation and stabiliza-
tion pathways, rather than simply being modulated by the ac-
tivity of degradation pathways, and that these processes are
active in both resting and LPS-stimulated cells.
Four phosphorylation sites have been identified in human
CARHSP1: serines 30, 32, 41, and 52, corresponding to mouse
serines 31, 33, 42, and 53. Serines 30 and 32 are dephosphor-
ylated by increases in intracellular calcium, an event that is
mediated by calcineurin (17). In contrast, serine 42 is dephos-
phorylated by an ionomycin-mediated calcium flux indepen-
dent of calcineurin (17), while serine 52 is not dephosphory-
lated by increased intracellular calcium (17), indicating that
this site operates independently of calcineurin. In vivo, serine
52 is phosphorylated by the PI3K-Akt pathway (2). Other stud-
ies have demonstrated that CARHSP1 is desphosphorylated by
stimuli that increase cAMP and this process is inhibited by
cyclosporine, FK506, okadaic acid, fostriecin, and calyculin A
(2, 13). Our data indicate that with regard to TNF- mRNA
stability, the activities of both calcineurin and Akt (Fig. 6) are
critical for CARHSP1 function. We are currently in the pro-
cess of generating serine-to-alanine mutations of all four
phosphorylation sites in all combinations to fully understand
the role of the different sites in CARHSP1-mediated TNF-
mRNA stabilization. These studies should assist in delineat-
ing the role of the different signaling pathways involved in
CARHSP1 regulation of TNF- posttranscriptional control.
The subcellular localization of CARHSP1 is also informa-
tive. While we cannot with complete certainty exclude the
possibility that a small percentage of CARHSP1 is present on
the polysomes, the localization of CARHSP1 to the less-dense
components of the cytoplasm, and not the nucleus, indicates
that CARHSP1 is not bound to the TNF- message when it is
exported from the nucleus and that it is not associated with
actively translating messages. It is also clear that LPS stimula-
tion does not increase CARHSP1 protein levels or shift the
protein onto or off the polysomes. Thus, the interaction of
CARHSP1 with the TNF-message, which clearly occurs since
CARHSP1 was identified in a screen for TNF- 3UTR-inter-
acting proteins, takes place following translation. This could
occur either following the pioneer round of translation for
messages destined for immediate decay by the standard
mRNA decay pathways, such as ARE-mediated decay, or fol-
lowing the termination of regular translation. The association
of CARHSP1 with P-bodies and exosomes, the sites of cyto-
plasmic mRNA decay, positions it to inhibit the decay process.
We examined the cytoplasmic/nuclear localization of HuR and
TTP in wild-type, control shRNA, and CARHSP1 shRNA cells
but found no difference (data not shown). The finding that
P-body and exosome components interact has not, to the best
of our knowledge, been previously demonstrated. Given the
role of each structure in different RNA decay pathways, in-
cluding nonsense-, non-stop-, no-go-, and ARE-mediated de-
cay, it is not surprising that a subset of these structures colo-
calize.
Recognizing that a great deal of work on the biology and
biochemistry of CARHSP1 remains to be understood, our cur-
rent model of CARHSP1 function is as follows. CARHSP1
interacts with the TNF- mRNA at the sites of mRNA degra-
dation, where it presumably prevents decay, allowing the mes-
sage to enter or reenter the translating pool of mRNA; this
function is regulated at least in part by calcineurin and Akt. It
is possible that CARHSP1 is a component of the pathway
involving HuR-mediated stabilization; however, it is also pos-
sible that CARHSP1 is part of a separate stabilization pathway
in the same way that the TNF-message is destabilized by TTP
(8) and AUF1 (26) through the ARE and at least one unknown
protein through the constitutive decay element (25). The data
presented here demonstrate that both mRNA decay and
mRNA stabilization are active, regulated processes and it is
the sum of the activity of stabilization and decay that estab-
lishes the half-life of a message.
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FIG. 9. CARHSP1 localizes to exosomes, and exosomes and P-
bodies colocalize. (A) CARHSP1 (green) colocalizes with the exosome
markers Rrp45 (red) and Rrp44 (blue) in resting RAW284.7 cells. The
boxes in the center are an enlargement of the white square in the
flanking panel. (B) CARHSP1 (green) colocalizes with the exosome
markers Rrp45 (red) and Rrp44 (blue) in LPS-stimulated (2 h)
RAW284.7 cells. (C) The structural exosome component Rrp45 (red)
colocalizes with the processing body marker Ge-1 (blue) in resting
RAW264.7 cells. (D) The structural exosome component Rrp45 (red)
colocalizes with the processing body marker Ge-1 (blue) in LPS-stim-
ulated (2 h) RAW264.7 cells.
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